Glutamate for Metabolic Intervention in Coronary Surgery II

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-10-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: failureheartiicoronarysurgery
  Phrases that lowered it: daymoderateevaluatefoodplasma
• Sponsor's past termination rate: 3.7% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Collaborators: 3 (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 18.1% (lowers risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Maximum age: 85 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 92.4% (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 10 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF NCT04560309 · started 2021 · scored riskier than 52% of active trials completed
• Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass NCT01478126 · started 2012 · scored riskier than 26% of active trials completed
• Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery NCT00966654 · started 2008 · scored riskier than 89% of active trials terminated
• Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG NCT03252093 · started 2017 · scored riskier than 86% of active trials terminated
• Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass NCT01373216 · started 2011 · scored riskier than 18% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.